Drug intelligence / Profile preview

Amonerve

Development stage: Unknown
Lead developer: AS Pharmaceutical
Modality: Small Molecules
Administration: Oral

Overview

**Amonerve** is an orally administered fixed-dose nutraceutical/pharmaceutical combination marketed by AS Pharmaceutical. A third-party product listing describes an Amonerve tablet containing alpha-lipoic acid, chromium picolinate, folic acid, methylcobalamin, myo-inositol, selenious acid, and zinc sulfate. AS Pharmaceutical lists Amonerve among its products, while a manufacturer directory associates the brand with chromium picolinate. Public sources reviewed do not establish a product-specific therapeutic indication or a single defined molecular target. ([sayacare.in](https://sayacare.in/brand/amonerve-tablet-69126))

Brand names: Amonerve

Targets

MTHFR (Methylenetetrahydrofolate reductase)GPX4 (Glutathione peroxidase 4)Misfolded SOD1INSR (Insulin receptor)MTR (Methionine synthase)

Beyond the preview

Go deeper on Amonerve.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Amonerve.

Explore the full profile